HIV-1 Remission: Accelerating the Path to Permanent HIV-1 Silencing
- PMID: 38005849
- PMCID: PMC10674359
- DOI: 10.3390/v15112171
HIV-1 Remission: Accelerating the Path to Permanent HIV-1 Silencing
Abstract
Despite remarkable progress, a cure for HIV-1 infection remains elusive. Rebound competent latent and transcriptionally active reservoir cells persevere despite antiretroviral therapy and rekindle infection due to inefficient proviral silencing. We propose a novel "block-lock-stop" approach, entailing long term durable silencing of viral expression towards an irreversible transcriptionally inactive latent provirus to achieve long term antiretroviral free control of the virus. A graded transformation of remnant HIV-1 in PLWH from persistent into silent to permanently defective proviruses is proposed, emulating and accelerating the natural path that human endogenous retroviruses (HERVs) take over millions of years. This hypothesis was based on research into delineating the mechanisms of HIV-1 latency, lessons from latency reversing agents and advances of Tat inhibitors, as well as expertise in the biology of HERVs. Insights from elite controllers and the availability of advanced genome engineering technologies for the direct excision of remnant virus set the stage for a rapid path to an HIV-1 cure.
Keywords: HERV; HIV-1 cure; latency; transcriptional silencing.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Tannic acid reactivates HIV-1 latency by mediating CBX4 degradation.J Virol. 2025 Jan 31;99(1):e0117324. doi: 10.1128/jvi.01173-24. Epub 2024 Dec 18. J Virol. 2025. PMID: 39692477 Free PMC article.
-
Genome-wide CRISPR knockout screen identifies activating transcription factor (ATF1) as an activator of HIV gene expression.mBio. 2025 Aug 13;16(8):e0055725. doi: 10.1128/mbio.00557-25. Epub 2025 Jul 3. mBio. 2025. PMID: 40607797 Free PMC article.
-
Forging a Functional Cure for HIV: Transcription Regulators and Inhibitors.Viruses. 2022 Sep 7;14(9):1980. doi: 10.3390/v14091980. Viruses. 2022. PMID: 36146786 Free PMC article. Review.
-
Advancements in single-cell techniques for examining the HIV reservoir: pathways to a cure.mBio. 2025 Jul 9;16(7):e0065525. doi: 10.1128/mbio.00655-25. Epub 2025 Jun 9. mBio. 2025. PMID: 40488537 Free PMC article. Review.
-
Structured treatment interruptions (STI) in chronic unsuppressed HIV infection in adults.Cochrane Database Syst Rev. 2006 Jul 19;2006(3):CD006148. doi: 10.1002/14651858.CD006148. Cochrane Database Syst Rev. 2006. PMID: 16856117 Free PMC article.
Cited by
-
Advancing Toward a Human Immunodeficiency Virus Cure: Initial Progress on a Difficult Path.Infect Dis Clin North Am. 2024 Sep;38(3):487-497. doi: 10.1016/j.idc.2024.06.001. Epub 2024 Jul 4. Infect Dis Clin North Am. 2024. PMID: 38969530 Review.
-
The relationship between HERVs and exogenous viral infections: A focus on the value of HERVs in disease prediction and treatment.Virulence. 2025 Dec;16(1):2523888. doi: 10.1080/21505594.2025.2523888. Epub 2025 Jul 1. Virulence. 2025. PMID: 40590391 Free PMC article. Review.
-
Human endogenous retroviruses and exogenous viral infections.Front Cell Infect Microbiol. 2024 Sep 27;14:1439292. doi: 10.3389/fcimb.2024.1439292. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 39397863 Free PMC article. Review.
-
HIV-1 Proviral Genome Engineering with CRISPR-Cas9 for Mechanistic Studies.Viruses. 2024 Feb 13;16(2):287. doi: 10.3390/v16020287. Viruses. 2024. PMID: 38400062 Free PMC article.
-
Integrator complex subunit 12 knockout overcomes a transcriptional block to HIV latency reversal.Elife. 2025 Apr 10;13:RP103064. doi: 10.7554/eLife.103064. Elife. 2025. PMID: 40207620 Free PMC article.
References
-
- Oomen P.G.A., Dijkstra S., Hofstra L.M., Nijhuis M.M., Verbon A., Mudrikova T., Wensing A.M.J., Hoepelman A.I.M., Van Welzen B.J. Integrated analysis of viral blips, residual viremia, and associated factors in people with HIV: Results from a retrospective cohort study. J. Med. Virol. 2023;95:e29178. doi: 10.1002/jmv.29178. - DOI - PubMed
-
- Singh K., Natarajan V., Dewar R., Rupert A., Badralmaa Y., Zhai T., Winchester N., Scrimieri F., Smith M., Davis I., et al. Long-term persistence of transcriptionally active ‘defective’ HIV-1 proviruses: Implications for persistent immune activation during antiretroviral therapy. AIDS. 2023;37:2119–2130. doi: 10.1097/QAD.0000000000003667. - DOI - PMC - PubMed
-
- Mavigner M., Delobel P., Cazabat M., Dubois M., L’Faqihi-Olive F.E., Raymond S., Pasquier C., Marchou B., Massip P., Izopet J. HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. PLoS ONE. 2009;4:e7658. doi: 10.1371/journal.pone.0007658. - DOI - PMC - PubMed
MeSH terms
Grants and funding
- P01 AI169606/AI/NIAID NIH HHS/United States
- UM1 AI164559/AI/NIAID NIH HHS/United States
- R01 DA052027/DA/NIDA NIH HHS/United States
- R21 AI172060/AI/NIAID NIH HHS/United States
- R01 AI167732/AI/NIAID NIH HHS/United States
- R01 CA260691/CA/NCI NIH HHS/United States
- R37 AI083139/AI/NIAID NIH HHS/United States
- K01 OD031900/OD/NIH HHS/United States
- R37 AI165137/AI/NIAID NIH HHS/United States
- R21 AI170166/AI/NIAID NIH HHS/United States
- P30 AI036214/AI/NIAID NIH HHS/United States
- R01 DK131526/DK/NIDDK NIH HHS/United States
- R01 AI147777/AI/NIAID NIH HHS/United States